

Republic of the Philippines Department of Health OFFICE OF THE SECRETARY

APR 0 7 2020

ADMINISTRATIVE ORDER No. 2020 - 0014-

SUBJECT : <u>Guidelines in Securing a License to Operate a COVID-19 Testing</u> Laboratory in the Philippines

I. RATIONALE/BACKGROUND

The current pandemic, Coronavirus Disease 2019 (COVID-19), has focused the attention on the scarcity of capable testing facilities. Local data, as of April 1, 2020, showed that there are 227 additional new confirmed cases with positive test results, bringing the number to 2,311 infected cases in the country, with 50 individuals recovering from the disease and 96 deaths reported.

The standard testing procedure for detecting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, is the Real Time Reverse Transcriptase – Polymerase Chain Reaction (rRT-PCR) as recommended by the World Health Organization (WHO). Its sensitivity to detect the presence of the virus early on will result in the immediate enforcement of precautionary measures, thus curbing the further transmission of the disease. It is a highly delicate process involving several steps to detect RNA viruses. As such, handling of specimens requires strict adherence to biosafety and biosecurity guidelines by WHO.

There are only few molecular laboratories in the country, and their services include genotyping, identifying mutation defects, deoxyribonucleic acid (DNA) sequencing and paternity testing. However, only the Research Institute for Tropical Medicine (RITM) has the laboratory recognized by the WHO as capable of doing COVID-19 testing.

These guidelines are being issued to set the standards in licensing COVID-19 testing laboratories as a strategy to expand testing capacity, to have more capable laboratories, and at the same time ensuring that quality and safety are maintained.

II. OBJECTIVE

This Order aims to ensure the safety of personnel and the general public, as well as the quality and accuracy of the generated reports of COVID-19 testing laboratories.

III. SCOPE

This Order shall apply to all private and government COVID-19 testing laboratories in the Philippines, whether hospital-based or non-hospital-based.

CERTIFIED TRUE COPY APR 15,2020 CORAZO Building A, San Lazaro Compound, Rizal Avenue, Sta. Cruz, 1003 Manila • Trunk Line 8651-7800 local 1108, 1111, 1112, 1113 KMTTS - RECORDS Direct Line: 711-9502; 711-9503 Fax: 743-1829 • URL: http://www.doh.gov.ph; e-mail: ftduque@doh.gov.ph Conariment of Health

IV. DEFINITION OF TERMS

- 1. Applicant an individual, partnership, corporation or association seeking a license to operate to maintain a COVID-19 testing laboratory.
- COVID-19 testing laboratory a health facility where COVID-19 testing (SARS-CoV-2 detection) is done on specimens from the human body to obtain information about the health status of a patient for the prevention, diagnosis and treatment of disease.
- 3. Department of Health-License to Operate (DOH-LTO) a formal authorization issued by the DOH through the Health Facilities and Services Regulatory Bureau (HFSRB) to an individual, partnership, corporation or association seeking to perform SARS-CoV-2 detection in a COVID-19 testing laboratory in compliance with the requirements prescribed in this Order.
- 4. **DOH-Permit to Construct** a permit issued by DOH through HFSRB to an applicant who will establish and operate a COVID-19 testing laboratory, upon compliance with required documents set forth in this Order prior to actual construction of the said facility. A DOH-PTC is also required for health facility with substantial alteration, expansion, renovation, etc. It is a prerequisite for License to Operate.
- 5. Letter of Recommendation a formal endorsement issued by RITM or its duly recognized/authorized assessors upon full compliance of the applicant with their requirements, which includes proficiency testing of the laboratory.
- 6. Real Time Reverse Transciptase Polymerase Chain Reaction (rRT-PCR) a PCR test designed to detect, measure and study RNA viruses. It allows a single strand of RNA to be translated into a complementary DNA which will then be amplified following the routine PCR method.

V. IMPLEMENTING MECHANISMS

A. GENERAL GUIDELINES

CENTIFIED TRUE COP

- 1. COVID-19 testing shall only be done in a DOH licensed COVID-19 testing laboratory.
- 2. The DOH-LTO for a COVID-19 testing laboratory shall only be issued upon full compliance to the standards and requirements of RITM and HFSRB/CHD-RLED.
- 3. The DOH-LTO of a hospital-based COVID-19 testing laboratory shall be subsumed in the LTO of the hospital.
- 4. For non-hospital-based COVID-19 testing laboratory:
 - a. With existing licensed general clinical laboratory the DOH-LTO of COVID-19 testing laboratory shall be subsumed in the current LTO of the general clinical laboratory.
 - b. For facilities with Certificate of Registration by the DOH or without any DOH regulatory authorization – the DOH-LTO of COVID-19 testing laboratory shall be issued as clinical laboratory with limited service capability.

J₂

- 5. The COVID-19 testing laboratory shall be a separate unit, with its own designated working room.
- 6. Strict adherence to biosafety and biosecurity guidelines, as prescribed by the RITM based on WHO recommendations, shall be strictly enforced.

- 7. The COVID-19 testing laboratory shall be supervised by a Board Certified Clinical Pathologist, with training in Molecular Laboratory Diagnosis.
- 8. The staff shall have the appropriate trainings prescribed by RITM.
- 9. COVID-19 testing laboratories shall have a Manual of Operations, which shall include, but not limited to, the standard operating procedures being implemented in the facility; policies and procedures on biosafety and biosecurity, handling and transporting of specimens; disposal of infectious wastes; Infection Prevention and Control; records management; preventive maintenance of the facility and the equipment; and copies of relevant laws and DOH issuances.
- 10. COVID-19 testing laboratories shall only use FDA registered testing kits, reagents and devices.
- 11. COVID-19 testing laboratories shall adhere and ensure strict compliance with infection prevention and control guidelines.
- 12. COVID-19 testing laboratories shall be strictly prohibited from outsourcing of examinations.
- 13. In reporting of results, COVID-19 testing laboratories shall follow DOH Department Memorandum No. 2020-0110 dated March 13, 2020, titled "Directive to All Public and Private hospitals and Healthcare Facilities on Reporting Coronavirus Disease (COVID-2019)"
- 14. COVID-19 testing laboratories shall follow the standards, criteria and requirements prescribed in the DOH Assessment Tool for Licensing a COVID-19 testing laboratory (ANNEX A), RITM's Biosafety and Laboratory Assessment Tool (ANNEX B1 and ANNEX B2), and accomplish the WHO risk assessment form (ANNEX C).

B. SPECIFIC GUIDELINES

1. CLASSIFICATION OF COVID-19 TESTING LABORATORIES

- A. According to Ownership
 - a) Government created by law. A government facility may be under the national government, DOH, local government unit (LGU), Department of National Defense (DND), Philippine National Police (PNP), Department of Justice (DOJ), State Universities and Colleges (SUCs), Government Owned and Controlled Corporations (GOCCs) and others.
 - b) Private owned, established and operated with funds through donation, principal, investment or other means by any individual corporation, association or organization. A private health facility may be a single proprietorship, partnership, corporation, cooperative, foundation, religious, non-government organization and others.

B. According to Institutional Character

- a) Hospital Based within the premises or the compound of the hospital. It may be a part of the general clinical laboratory, but with a specific designated room distinct from the main laboratory.
- b) Non-hospital-based located outside the premises or the compound of a hospital and independently functioning on its own.



nof

2. STANDARDS

COVID-19 testing laboratories shall be organized to provide safe, quality and effective and efficient services.

A. PERSONNEL

There shall be an adequate number of personnel, depending on the workload.

- 1. The minimum number of personnel shall be SEVEN (7), but may be more depending on the workload, and shall be composed of the following:
 - a) One (1) Board Certified Clinical Pathologist with knowledge in Infectious Diseases and training in Molecular Laboratory Diagnosis;
 - b) Three (3) Full-time Analysts per eight (8) hour shift, which shall be composed of EITHER three (3) Registered Medical Technologists OR two (2) Registered Medical Technologists and any allied health professionals with a Bachelor's degree relevant to the job, and with knowledge, experience, and skills in molecular biology techniques, such as Molecular Biology and Biotechnology, Biology, Applied Biology, Biochemistry, and Microbiology;
 - c) One (1) Full-time Laboratory Aide per eight (8) hour shift;
 - d) One (1) Full-time Receptionist per eight (8) hour shift; AND
 - e) One (1) Full-time Encoder per eight (8) hour shift.
- 2. The laboratory staff shall have the following trainings:
 - a) Fundamentals of Biosafety and Biosecurity, which shall cover Biological Risk Assessment, Mitigation Controls (engineering, practices and procedures, administrative), Personal Protective Equipment, specimen transport, waste management, decontamination and disposal, and Emergency Responses (biological spill drill), AND
 - b) Molecular Diagnostics.
- 3. The staff shall be proficient on Molecular Diagnostic Techniques.
- 4. The staff shall undergo fit testing for respirator with at least 95% efficiency e.g. N95 mask.
- 5. The staff shall have an annual medical examination including influenza vaccination.
- 6. The staff shall have continuing updated trainings on biosafety and biosecurity, new techniques and technologies, among others.

B. PHYSICAL FACILITIES

COVID-19 testing laboratories shall have adequate and appropriate areas to safely, effectively and efficiently provide the services to clients.

- 1. There shall be a dedicated space for each of the following activities:
 - a) Specimen reception;
 - b) Virus inactivation and nucleic acid extraction (Pre-PCR);
 - c) Reagent storage and handling;
 - d) PCR; AND
 - e) Clerical activities.

APR 15 2020 (ARUL G CORAZON S. DELA CRUZ KMITS - RECORDS SECTOR Mains - RECORDS SECTOR Mains - RECORDS SECTOR

CERTIFIED TRUE COPY

- 2. Unidirectional workflow following the abovementioned activities shall be maintained at all times.
- 3. The prototype floor plan and the floor plan checklist for constructing a COVID-19 testing laboratory shall be used as references in constructing the testing laboratory. (ANNEX D1 and ANNEX D2)
- 4. Controlled and adequate ventilation with the prescribed air changes per hour shall be maintained for each specific area.
- 5. Adequate lighting shall be provided in all areas.

3. EQUIPMENT AND INSTRUMENTS

COVID-19 testing laboratories shall have available and operational equipment and instruments appropriate and consistent to the designated areas. (Please refer to Annex A – Assessment Tool for Licensing a COVID-19 testing laboratory) They shall comply with or have:

- 1. Required equipment, supplies and reagents are organized and appropriately located in their designated areas.
- 2. There shall be a documented inventory of equipment, supplies, reagents and control.
- 3. Periodic calibration and maintenance of equipment are carried out and duly documented.
- 4. The equipment shall undergo daily cleaning and maintenance.

4. SERVICE CAPABILITY

COVID-19 testing laboratories shall ensure that the services delivered to patients comply with the standards in the Assessment Tool for Licensing a COVID-19 testing laboratory (ANNEX A) and other relevant issuances. They must have:

- 1. Manual of Procedures and Work Instructions on the laboratory techniques.
- 2. Accomplished WHO Risk Assessment form.
- 3. Standard Operating Procedures of the facility, which shall include, but not limited to, Policies on Biosafety and Biosecurity; proper use of Personal Protective Equipment; Specimen Storage, Transport and Disposal; Waste Management; Emergency Response System (accidents, medical emergencies, spills, natural disasters, facility containment).
- 4. A copy (soft or hard copy) of RITM Biorisk Management Office Interim Biosafety Guidelines for Laboratories Handling and Testing SARS-COV-2 (COVID-19) Specimen Version 2 or its latest version.

5. QUALITY IMPROVEMENT ACTIVITIES

COVID-19 testing laboratories shall establish and maintain a system for continuous quality improvement activities, and be able to:

- 1. Pass the proficiency testing given by RITM prior to its operation.
- 2. Identify the many potential risks in the laboratory processes and document the recommendations to mitigate such risks.
- 3. Participate and pass in the National External Quality Assessment Scheme (NEQAS) given by RITM.



6. INFORMATION MANAGEMENT

Every COVID-19 testing laboratory shall maintain a system of communication, recording, reporting and releasing of the patient's results, in adherence to Republic Act (R.A.) No. 10173 also known as the "Data Privacy Act of 2012" **AND** R.A. No. 11332 also known as the "Mandatory Reporting of Notifiable Diseases and Health Events of Public Health Concern Act".

There shall be logbook or record for:

- 1. Receiving of specimen with laboratory request from the health facility or attending physician.
- 2. Specimen storage, transport, and disposal.
- 3. Releasing of results to the DOH Epidemiology Bureau (EB) and DOH Regional Epidemiologic Surveillance Unit (RESU).
- 4. Sentinel/adverse events.
- 5. Preventive and corrective maintenance of equipment and instruments.
- 6. Maintenance and monitoring of health facility.

7. ENVIRONMENTAL MANAGEMENT

COVID-19 testing laboratories shall ensure that the environment is safe for its patients and staff, including the general public.

- 1. There shall be a written plan and program of proper disinfection and preventive maintenance of the facility.
- 2. There shall be appropriate signage, and that only authorized personnel shall be allowed entry.
- 3. The use of Personal Protective Equipment and adherence to Infection Control Policies shall be strictly observed.
- 4. There shall be procedures for the proper disposal of infectious wastes and toxic and hazardous substances in accordance with R.A. No. 6969 known as "Toxic and Hazardous Substances and Nuclear Wastes Act" and other related policy guidelines and/or issuance (e.g. DOH Healthcare Waste Management Manual).
- 5. There shall be a Memorandum of Agreement with infectious waste and toxic and hazardous substances hauler.

8. CONTINGENCY PLAN

Every COVID-19 testing laboratory shall have a contingency plan in case of equipment breakdown and shall have a Notarized Memorandum of Agreement (MOA) with another DOH licensed COVID-19 testing laboratory.

- 1. The COVID-19 testing laboratory shall inform in writing the DOH-HFSRB or CHD-RLED about the temporary suspension of their COVID-19 testing.
- 2. In case of equipment breakdown during the actual processing of specimens, the sample shall be immediately transported (in strict adherence to the guidelines for specimen handling and transport) to another COVID-19 testing laboratory, which they have a MOA with



- 3. In the event of machine breakdown, the COVID-19 testing laboratory shall not accept specimens from any patient or referral health facility.
- 4. The COVID-19 testing laboratory shall inform their clients and refer them to another DOH licensed COVID-19 testing laboratory.
- 5. Full operation shall be restored within three (3) months.

RELEASE OF RESULTS 9.

- 1. Results shall be signed by the medical technologist who performed the test, verified by a senior technologist, and approved by the pathologist prior to release.
- 2. Releasing of results shall follow the DOH guidelines.
- 3. The Laboratory shall submit a linelist of POSITIVE specimens following the linelist format below:

Name of COVID-19 Testing Laboratory:

Date of Report:

LAB ID	PATIENT NAME	AGE	SEX	HEALTH FACILITY	SPECIMEN TYPE	PCR RESULT
COVIDID-XXXX	Dela Cruz, Juan	40	М	Hospital A	NPS/OPS	SARS-CoV-2 viral RNA detected
COVIDID-XXXX	Cruz, Gabriella	60	F	Hospital B	NPS/OPS	SARS-CoV-2 viral RNA detected

4. The linelist of POSITIVE specimens shall be e-mailed to the following:

- a) Usec. Myrna Cabotaje mcc6277@gmail.com
- b) DOH Epidemiology Bureau 2019.ncov.central@gmail.com
- c) Director of the Hospital
- d) Appropriate Regional Epidemiology and Surveillance Unit (RESU)
- e) Dr. Celia Carlos <u>ccarlosphl@yahoo.com</u>
- 5. The Laboratory shall submit a linelist of NEGATIVE specimens following the linelist format below:

Name of COVID-19 Testing Laboratory:

Date of Report:

LAB ID	PATIENT NAME	AGE	SEX	HEALTH FACILIT <u>Y</u>	SPECIMEN TYPE	PCR RESULT
COVIDID-XXXX	Dela Cruz, Juan	40	M	Hospital A	NPS/OPS	SARS-CoV-2 viral RNA not detected
COVIDID-XXXX	Cruz, Gabriella	60	F	Hospital B	NPS/OPS	SARS-CoV-2 viral RNA not detected

6. The linelist of NEGATIVE specimens shall be e-mailed to the following: a) DOH Epidemiology Bureau – 2019.ncov.central@gmail.com

- b) Director of the Hospital
- c) Appropriate Regional Epidemiology and Surveillance Unit (RESU)
- d) Dr. Celia Carlos ccarlosphl@yahoo.com

VI. PROCEDURAL GUIDELINES

Licensing Process 1.

- a. DOH-Permit to Construct (DOH-PTC)
 - 1) A DOH PTC shall be a prerequisite in the application of LTO.
 - A DON-1 Comment of the submitted to:
 A completely filled out application form shall be submitted to:

CERTIFIED TRUE COPY APR 15 2020 ORAZON S. DEL KMITS - RECORDS Department of Hea

- a. HFSRB for COVID-19 testing laboratories based in levels 2 and 3 general hospitals, and specialty hospitals;
- b. CHD-RLEDs for non-hospital based COVID-19 testing laboratories and for COVID-19 testing laboratories based in level 1 general hospitals.
- Complete applications (based on A.O. No. 2016-0042, "Guidelines in Securing a DOH-PTC") shall be processed according to the Citizen's Charter timeline.
- 4) Once approved, the facility owners can commence with the construction of the laboratory.
- b. DOH-License to Operate (DOH-LTO)
 - 1) Filing of complete application requirements, whether manual or online, shall be at HFSRB or CHD-RLEDs.
 - a. HFSRB for COVID-19 testing laboratories based in levels 2 and 3 general hospitals, and specialty hospitals;
 - b. CHD-RLEDs for non-hospital based COVID-19 testing laboratories and for COVID-19 testing laboratories based in level 1 general hospitals.
 - 2) Complete documentary requirements shall consist of the following:
 - a. Notarized completely accomplished application form (ANNEX E);
 - b. A copy of approved DOH-PTC and floor plan;
 - c. Notarized list of personnel, including photocopies of valid PRC identification card, valid COVID-19 proficiency training certificate from RITM, and copy of certificates of all necessary trainings;
 - d. List of equipment with specifications, reagents, and supplies;
 - e. Copy of Certificate of Product Registration (CPR) from Food and Drug Administration for all equipment, reagents and supplies;
 - f. Accomplished Self-Assessment Tool for Licensing a COVID-19 testing laboratory;
 - g. For renewal, a copy of NEQAS, Certificate of Performance with PASSING results, conducted by RITM.
 - 3) After evaluation of the submitted documents for technical completeness and correctness, the assigned team from HFSRB/CHD-RLED shall schedule an inspection date, in coordination with the team from RITM or its duly recognized/authorized 3rd party assessors.
 - 4) Process for Inspection (initial or renewal) shall follow Section VI. E and F of A.O. No. 2012-0012, known as "Rules and Regulations Governing the New Classification of Hospitals and Other Health Facilities in the Philippines" and the Quality Management System (QMS) guidelines of the Bureau.
 - 5) RITM or its duly recognized/authorized 3rd party assessors shall transmit to HFSRB/CHD-RLED a Letter of Recommendation when the facility is fully compliant to the standards and requirements of RITM.
 - 6) The DOH-LTO a COVID-19 testing laboratory shall be issued only after full compliance to the standards and requirements by HFSRB/CHD-RLED and the RITM.



- 7) The DOH-LTO shall be signed by the Director IV of HFSRB or CHD-RLED.
- 8) Processing from application to issuance of DOH-LTO shall be according to the Citizen's Charter Timeline.
- 2. Validity of DOH-LTO

The DOH-LTO, for both hospital-based and non-hospital-based COVID-19 testing laboratory, shall be valid for one (1) year. Annual renewal of DOH-LTO COVID-19 testing laboratory shall follow the annual cut-off dates as prescribed in A.O. no. 2019-0004 dated April 30, 2019, titled "Guidelines on the Annual Cut-off Dates for Receipt of Complete Applications for Regulatory Authorizations Issued by the Department of Health."

3. Monitoring

HFSRB/CHD-RLED together with RITM or its duly recognized/authorized 3rd party assessors may conduct unannounced visits to ensure continuous compliance to the standards.

4. Fees

- 1. The DOH-LTO fee shall follow the schedule of fees currently prescribed by the DOH.
- 2. The applicant, upon filing the application, shall pay the corresponding fee to the DOH Cashier/RO Cashier.

VII. ROLES AND RESPONSIBILITIES

1. Health Facilities and Services and Regulatory Bureau

- a. To strictly enforce the provisions of this Order.
- b. To set standards for the regulation of health facilities including COVID-19 testing laboratories.
- c. To create/modify inspection and monitoring tools from time to time.
- d. To disseminate regulatory policies, standards and forms for information and guidelines to the DOH-CHDs.
- e. To provide consultation and technical assistance to stakeholder, including regulatory officers from the DOH-CHDs in regulation of COVID-19 testing laboratories.
- f. To inspect and issue DOH-LTO for COVID-19 testing laboratories based in levels 2 and 3 general hospitals, and specialty hospitals.
- g. To conduct unannounced monitoring visits to check for continuous compliance of DOH-LTO.
- h. To promptly respond to complaints relative to the operation of COVID-19 testing laboratories.
- 2. Research Institute of Tropical Medicine (RITM) the reference laboratory for COVID-19 testing recognized by the World Health Organization (WHO)
 - a. To provide laboratory reference / referral services for COVID-19.
 - b. To train laboratory personnel.
 - c. To maintain quality assurance program for COVID-19 testing laboratories through proficiency testing.
 - d. To perform technical evaluation of reagents and diagnostic kit.

CERTIFIED TRUE COP

- e. To train & authorize 3rd party trainer and/or assessors.
- 3. Center for Health Development Regulation, Licensing, and Enforcement Division (CHD-RLED)
 - a. To strictly enforce the provisions of this Order.
 - b. To inspect and issue DOH-LTO CHD-RLEDs for non-hospital based COVID-19 testing laboratories and for COVID-19 testing laboratories based in level 1 general hospitals.
 - c. To conduct unannounced monitoring visits to check for continuous compliance of COVID-19 testing laboratories.
 - d. To submit report on Suspension/Revocation/Cease and Desist Order issued on COVID-19 testing laboratories as soon as possible.
 - e. To promptly respond to complaints relative to the operation of COVID-19 testing laboratories.
- 4. Epidemiology Bureau and its Regional Epidemiology Surveillance Units a. Collect and aggregate data from COVID-19 testing laboratories.
 - b. Analyze and report data collected from COVID-19 testing laboratories.

VIII. TRANSITORY PROVISIONS

In view of the urgency of the need for more COVID 19 testing laboratories:

- a) The DOH-PTC application shall be waived for existing facilities and shall submit an as built floor plan, in lieu of the DOH-PTC which reflects the workflow on the prototype reference plan.
- b) All initial application shall be submitted to HFSRB whether hospital-based or non-hospital-based. However, renewal for COVID-19 testing laboratories in based in level 1 hospitals and non-hospital based shall be at their respective CHD-RLED.
- c) The technical assistance done by DOH, RITM or its duly recognized/authorized 3rd party assessors may serve as the initial inspection visit. As such, compliance to the recommendations done then and to the Assessment Tool for licensing a COVID-19 testing laboratory may preclude another visit prior to the issuance of DOH-LTO. A re-visit may be done by the team, if so warranted.
- d) The laboratories already assessed by the team from HFSRB/CHD-RLEDs are advised to apply for a DOH-LTO, using these guidelines as reference.
- e) Team to conduct inspection or monitoring shall come from HFSRB and RITM or its duly recognized/authorized 3rd party assessors.

IX. VIOLATION AND SANCTIONS

COVID-19 testing laboratories and/or the responsible personnel thereof, found to be violating any provision of these rules and regulations, related issuances, and other applicable policy guidelines, shall be penalized under the existing laws, which may include suspension or revocation of DOH-LTO.

X. APPEAL

Any hospital or health facility aggrieved by the decision of the Director IV of HFSRB, or in his/her absence or unavailability or when delegated, the Director III of HFSRB, may, within ten (10) days after receipt of the notice of decision, file a notice of appeal to the head of the Health Regulation Team (HRT). All pertinent documents and records of the applicant shall then be elevated by the HFSRB to the HRT. The



and a second

decision of the head of the HRT, if still contested, maybe brought on a final appeal to the Secretary of Health whose decision shall be absolute and executory.

XI. REPEALING CLAUSE

Previous issuances or any of their provisions which are inconsistent or contrary to the provisions of this issuance are hereby rescinded or modified accordingly.

XII. SEPARABILITY CLAUSE

In the event that any provision or part of this issuance is declared unconstitutional or rendered invalid by any court of law or competent authority, the portions not affected thereby shall remain in full force and effect.

XIII. EFFECTIVITY

This Order shall take effect immediately.

CISCO T. DUQUE III, MD, MSc Secretary of Health





Republic of the Philippines Department of Health HEALTH FACILITIES AND SERVICES REGULATORY BUREAU

ASSESSMENT TOOL FOR LICENSING A COVID-19 TESTING LABORATORY

INSTRUCTIONS:

- 1. To properly fill-out this tool, the Licensing Officer shall make use of: INTERVIEWS, REVIEW OF DOCUMENTS, OBSERVATIONS and VALIDATION of findings.
- 3. The REMARKS column shall document relevant observations.
- 4. Make sure to fill-in the blanks with the needed information. Do not leave any items blank.
- 5. The Team Leader shall ensure that all team members write down their printed names, designation and affix their signatures and indicate the date of inspection/monitoring, all at the last page of the tool.
- 6. The Team Leader shall make sure that the Head of the facility or, when not available, the next most senior or responsible officer likewise affix his/her signature on the same aforementioned pages, to signify that the inspection/monitoring results were discussed during the exit conference and a duplicate copy also received.

I. GENERAL INFORMATION:

Name of Facility:			
Address:			
(Number & Street)	(Barangay/District)	(Municipality/City)	
(Province &	Region)		
Telephone/ Fax No	E-mail Address:		
Initial:	Renewal:		
Existing License No:	Date Issued:	Expiry Date:	
Name of Owner or Governing Body (i	f corporation):		
Name of Head of Laboratory:			
Classification According to:			
Ownership: Go	vernment	Private	
Function:CO	VID-19 Testing Laboratory		
Institutional-Character:Ho	spital-Based	Non-hospital-based	
Service Capability: Add-o	n service to General Clinical	Laboratory	
Limit	ed Service Capability to COV	/ID-19 Testing	

CRITERIA	INDICATOR / EVIDENCE	COMPLIED	REMARKS
I. LEADERSHIP AND The provider organizati policies and has overall its resources	MANAGEMENT ion's management team provides leade l responsibility for the organization's o	rship, acts accord peration, and the	ing to the organization's quality of its services and
Organizational Structure/Chart	Observe • Organizational Structure / Chart is posted in conspicuous area.		
Mission, vision and objectives shall be in accordance with RA 4688	 Document Review Written vision, mission, and goals Observe Vision, mission, and goals displayed in a conspicuous area visible to clients 		
License to operate and other documents	 Document Review Compilation of Clinical Laboratory AOs, Report of Inspection/Monitoring 		
	 Observe Valid DOH-LTO posted in a conspicuous area visible to clients 		
Administrative and technical monitoring and Evaluation activities to assess management and organizational performance	 Document Review Supporting documents for evaluation and monitoring of activities such as records, logbooks, checklist of supplies, inspection report, purchasing or procurement and acceptance of supplies, etc. 		
Policy on Management Review – Conduct of regular staff meetings held at least twice a year or as needed.	 Document Review Compilation of minutes of meeting (reflecting the date, time, attendance, agenda and action taken signed and approved by head of laboratory 		
Procedures for handling complaints and client feedback	 Document Review Written protocol for handling complaints/ client feedback. Forms for complaints/ client feedback Suggestion box visible to clients Records of complaints/ client feedback and actions taken 		

-

.

.

•

CRITERIA	INDICATOR / EVIDENCE	COMPLIED	REMARKS
II. HUMAN RESOURC A. STAFF RECRUI There are relevant of management and st	CE MANAGEMENT TMENT, SELECTION, APPOINTN prientation, training and development p aff.	MENT AND RES programs to meet	PONSIBILITIES the educational needs of
Policy on continuing program for staff development and training	 Document Review Written policies and procedures for staff development and training Proof of training through relevant certificates, memos, written reports, budgetary allocations Interview Human Resources Management 		
Policy for hiring, orientation and promotion for all levels of personnel	Officer/Personnel Officer Document Review • Written policies and procedures on hiring, orientation and promotion of personnel at all levels		
Policy for discipline, suspension, demotion and termination of personnel at all levels	 Document Review Written policies and procedures on discipline, suspension, demotion and termination of personnel at all levels 		
B. MANPOWER The COVID-17 tes efficient laboratory	ting laboratory shall have an adequate services.	trained personnel	to provide effective and
The organizational chart shall be clearly structured.	 Document Review Updated organizational chart indicating the names with latest pictures (at least passport size) and designation, reflecting lines of authority, accountability, communication, interrelationship, hierarchy of functions and flow of referrals. 		
Duties and responsibilities shall be clearly spelled out.	 Document Review Written job description or duties and responsibilities of all laboratory personnel 		
Adequate number of qualified personnel with documented training and experience to conduct the laboratory procedures performed.	 Document Review List of Personnel with designation Area of assignments indicated in the posted work schedule signed and approved by head of laboratory Proof of attendance 		

.

CRITERIA	INDICATOR / EVIDENCE	COMPLIED	REMARKS
The head of the COVID-19 Testing Laboratory shall have the overall supervision on technical procedures as well as on the administrative laboratory management	Document Review • Proof of Supervisory visits at least once a week or as needed		
Each personnel shall have a record of updated 201 file	 Document Review Proof of qualifications 		
Head of the Laboratory (3) Analysts	 Resume PRC ID and Certificate PSP Board Certificate Training Certificate on Molecular Laboratory Diagnosis Notarized Employment Contract Annual Health Status (Latest Medical Certificate) Influenza Vaccination Resume PRC ID and Certificate Training Certificates on Molecular Laboratory Diagnosis and 		
	 Biosafety and Biosecurity Notarized Employment Contract Annual Health Status (Latest Medical Certificate) Influenza Vaccination 		
 (1) Laboratory Aide (1) Encoder (1) Receptionist 	 Resume Training Certificates on Biosafety and Biosecurity Notarized Employment Contract Annual Health Status (Latest Medical Certificate) Influenza Vaccination 		

.

-

III. PHYSICAL PLANT, FACILITIES, AND WORK ENVIRONMENT There an adequate space with a unidirectional workflow for the safe & efficient operation of the COVID-19 testing laboratory

······	- 		· · · · · · · · · · · · · · · · · · ·
CRITERIA	INDICATOR / EVIDENCE	COMPLIED	REMARKS
Program of proper maintenance and monitoring of physical plant and facilities	 Document Review Written policy and program for the proper maintenance and monitoring of physical plant and facilities Proposed schedule for preventive maintenance Observe 		
	• Updated proof of actual implementation of maintenance as to structure, ventilation, lighting & water supply		
Policy guidelines on laboratory biosafety and biosecurity	 Document Review Written protocols on laboratory biosafety and biosecurity 		
	 Observe Provision of Personal Protective Equipment Good Laboratory Practice that includes use of Personal Protective Equipment and other precautionary measures 		
Procedures for the proper disposal of waste and hazardous/infectious substances that shall conform to the standards set by the DOH	 Document Review Policy on disposal of wastes that conform with Healthcare Waste Management Manual, and RA6969 Notarized Memorandum of Agreement with infectious waste, toxic, and hazardous substances hauler 		
	 Observe Proof of proper management of wastes from point of generation, segregation (color-coded waste bins), disinfection, up to the final disposal 		
IV. EQUIPMENT /INST	RUMENTS		
I nere snall be adequate	Document Review	ang condition.	
Adequate number of operational equipment to provide the laboratory	• Equipment listed available in the laboratory		
laboratory is licensed for.	•Equipment are operational		

CRITERIA	INDICATOR / EVIDENCE	COMPLIED	REMARKS
Program for calibration, preventive maintenance and repair for the equipment.	 Document Review Record of schedule and updated certificate of calibration and maintenance of equipment Record of reports of preventive maintenance and repair 		
Contingency plan in case of equipment breakdown	 Document Review Written policy on contingency plan in case of equipment breakdown. 		
V. REAGENTS AND SI There shall be adequate operations.	PPLIES e reagents and supplies which are in go	od condition and	sufficient enough for the
Adequate supply of properly stored and inventoried reagents and supplies for the laboratory examinations to be provided.	 Document Review Quality records of supplies /reagents with expiration date, their usage/ consumption and disposal are available Certificate of Product Registration from Food & Drug Administration (FDA) Observe Availability and completeness of reagents and supplies Validate the expiration dates of reagents 		
Reagents and supplies are stored under the required conditions. Adequate storage facilities such as refrigerators for perishable reagents and supplies	 Document review Temperature monitoring records as follow: Room temperature reading Refrigerator and freezer temperature reading Observe Temperature within the laboratory Temperature of refrigerators and freezers 		
Appropriate storage area/technique for flammable, combustible and hazardous chemical/reagents	 Document review Material Safety Data Sheet (MSDS) available for all reagents/supplies and accessible to all personnel at all times Observe Organized per section with National Fire Protection Association (NFPA) Label 		

.

-

.

•

•

VI. ADMINSTRATIVE POLICIES AND PROCEDURES

.

Policies and procedures for provision of laboratory services are formulated for the operation and maintenance of the laboratory.

INDICATOR / EVIDENCE	COMPLIED	REMARKS
 Document review Documented policies, protocols, procedures signed and approved by the head of laboratory Guidelines in the operation and maintenance of the laboratory including policy on security of supplies, specimens and confidentiality of records 		
 Document review Documented and updated policies and procedures for provision of laboratory services in the laboratory and in each of the sections Documented policies, protocols, guidelines in the operation and maintenance of the laboratory 	· · · ·	
 Document review Documented procedures for receipt and performance of COVID-19 testing. 		
 Document review Documented procedures for reporting of results of COVID-19 testing. Compilation of reports to DOH- EB_RESU and RIM 		
 EB, RESO, and RIM. Document review Laboratory report forms bearing the name and original signature with PRC ID No. of the head. Laboratory reports bearing the name of RMT and original signature with PRC ID No. who performed the examinations and shall bear the name and signature of senior RMT who validated the report. Updated records of result (logbooks/ electronically stored data with back up) including entry, releasing & endorsement records. 		
	 INDICATOR / EVIDENCE Document review Documented policies, protocols, procedures signed and approved by the head of laboratory Guidelines in the operation and maintenance of the laboratory including policy on security of supplies, specimens and confidentiality of records Document review Documented and updated policies and procedures for provision of laboratory services in the laboratory and in each of the sections Documented policies, protocols, guidelines in the operation and maintenance of the laboratory ecords Document review Document review Documented procedures for receipt and performance of COVID-19 testing. Document review Document review Documented procedures for reporting of results of COVID-19 testing. Compilation of reports to DOH-EB, RESU, and RIM. Document review Laboratory report forms bearing the name and original signature with PRC ID No. of the head. Laboratory reports bearing the name of RMT and original signature with PRC ID No. who performed the examinations and shall bear the name and signature of senior RMT who validated the report. Updated records of result (logbooks/ electronically stored data with back up) including entry, releasing & endorsement records. 	INDICATOR / EVIDENCECOMPLIEDDocument reviewDocumented policies, protocols, procedures signed and approved by the head of laboratoryGuidelines in the operation and maintenance of the laboratory including policy on security of supplies, specimens and confidentiality of recordsDocument reviewDocument reviewDocument and updated policies and procedures for provision of laboratory services in the laboratory and in each of the sectionsDocumented policies, protocols, guidelines in the operation and maintenance of the laboratoryecordsDocument reviewDocumented procedures for receipt and performance of COVID-19 testing.Document procedures for reporting of results of COVID-19 testing.Document reviewLaboratory report forms bearing the name and original signature with PRC ID No. of the head.Laboratory reports bearing the name and original signature with PRC ID No. who performed the examinations and shall bear the name and signature of senior RMT who validated the report.Updated records of result (logbooks/ electronically stored data with back up) including entry, releasing & endorsement records.

CRITERIA	INDICATOR / EVIDENCE	COMPLIED	REMARKS
Procedures for reporting of work load, quality control, inventory control, etc	 Document review Documented procedures for reporting of work load, quality control, inventory control, etc. Updated reports, documents (Hard control and comparish back up) 		
	 Worksheets/ machine print out per section as proof of actual performance 		
Procedure for reporting and	Document review		
analysis of incidents, adverse events, etc.	• Documented procedures for reporting and analysis of incidents, adverse events, etc.		
	Compilation of written reports with resolutions		
The retention of records of	Document review		
the laboratory shall follow	• Documented procedure for the		
standards promulgated by	retention of records which follows		
the Department of Health	standards promulgated by the		
	Department of Health		÷.,
(DC# /0 s. 1996) and/or			·
Organizations			
B. Quality Assurance Pro	gram	; ~	
Policy on Quality	Document review		
Assurance	Documented Internal Quality		
Program and Continuous	Assurance Program including		
Quality Improvement	Internal Quality Control and		
	Continuous Quality Improvement		
	• Updated QC reports conducted		
	• Availability of reference materials		
	and appropriate reagents &		
1	equipment used		•
	• Results/findings of Quality		
	• Assurance audits/ assessments		
Participation in	Document review		
proficiency result	• Documented procedure in the		
to the operation of	testing		
licensed COVID-19	Certificate of Proficiency		
testing laboratory			
Participation in an	Document review		
National External Quality	• Documented procedure in the		
Assessment Scheme	actual performance of NEQAS		
conducted by RITM	activities		
	• Certificate of Performance in NEQAS with passing rate		

•

.

-

.

.

C. REFERRAL OF COVID-19 TESTING

When COVID-19 testing are referred to and provided by another COVID-19 testing laboratory, the referring COVID-19 testing laboratory shall obtain assurance of the quality of services provided through an agreement or its equivalent with a licensed COVID-19 testing laboratory performing the laboratory services needed.

Policy on referral and outsourcing of	Documented Procedures on referral and outsourcing of	
examinations	examinations to other licensed COVID-19 testing	
	laboratory	
	Records of outsourced COVID-19 examinations (In the event of	
	machine breakdown during actual process only)	
	Notarized Memorandum of Agreement	
	DOH license of referral COVID-19 testing laboratory	

PART II

LIST OF EQUIPMENT

- I. Laboratory Equipment, Furniture and Supplies Required
- 1. The facility should make sure that the following equipment/supplies/furniture are available at all times.

1.1. For Reagent Preparation

a. Equipment and supplies

The following are minimum recommended equipment for this workstation:

- □ PCR cabinet/laminar flow
- \square 4⁰C refrigerator for reagents
- \Box -20⁰C freezer for reagents
- □ Microcentrifuge
- □ Vortex mixer
- □ Minifuge
- \Box Cold rack for PCR tube
- □ Set of four adjustable-volume micropippettes with rack:100-1000 l, 20-200 ul, 2-20 ul, and 0.5-10ul
- ☐ Micropipette tips
- □ Gloves (different size: S,M,L)

The quantity of the above-mentioned may be increased depending on purpose, manpower and workload of the laboratory.

b. Laboratory furniture

- Bench space with leg room and storage for consumables
- □ Storage cabinets
- □ Laboratory chairs

1.2. For Specimen Handling/ Sample Preparation

a. Equipment and supplies

The following are minimum recommended equipment for this workstation:

- Biological Safety Cabinet Class II A2
- \square 4^oC refrigerator with -20^oC for specimens
- □ 4°C refrigerator with -20°C for nucleic acid extracts
- □ Microcentrifuge
- U Vortex mixer
- □ Minifuge
- □ Computer and printer for accessioning
- □ Cold rack for PCR tube
- □ Set of four adjustable-volume micropippettes with rack:100-1000 l, 20-200 ul,
- □ 2-20 ul, and 0.5-10ul
- □ Micropipette tips
- \Box Gloves (different size: S, M, L)

The quantity of the above-mentioned may be increased depending on purpose, manpower and workload of the laboratory.

b. Laboratory furniture

- □ Laboratory sink with drying rack
- Bench space with leg room and storage for consumables
- □ Storage cabinets
- □ Laboratory chairs

1.3. Amplification/PCR

a. Equipment

The following are minimum recommended equipment for this workstation:

- □ Real-time PCR machine
- □ Conventional PCR machine
- □ Minifuge
- Computer and printer (associated with the Real-time PCR machine)
- \Box -20⁰C or -40⁰C freezer for storage of PCR products

The quantity of the above-mentioned may be increased depending on purpose, manpower and workload of the laboratory.

b. Laboratory furniture

- **Laboratory sink with drying rack**
- Bench space with leg room and storage for consumables
- □ Storage cabinets
- □ Laboratory chairs



Republic of the Philippines Department of Health HEALTH FACILITIES AND SERVICES REGULATORY BUREAU

Name of Hea	lth Facility:		
Date of Inspe	ection:		
RECOMME A. For I	NDATIONS: Licensing Process		
[]	For Issuance of License to Op	erate as	
	Validity from	to	
[]	Issuance depends upon compl	iance to the recommendations given ar from the date of inspection	nd submission of the following within
		· · · · · · · · · · · · · · · · · · ·	
[]	Non-issuance. Specify reason	/s:	
Inspected b	Printed name	Signature	Position/Designation
		· · · · · · · · · · · · · · · · · · ·	
Received by	:		
Signature:			
Printed Nan	ne:		
Position/Des	signation:		
Date:		<u></u>	



Republic of the Philippines Department of Health HEALTH FACILITIES AND SERVICES REGULATORY BUREAU

Name of H	ealth Facility:		;;
Date of Mo	onitoring:		
RECOMM A. For	IENDATIONS: r Monitoring Process		
[]	Issuance of Notice of Violation		
		<u> </u>	
[]	Non-issuance of Notice of Violation		
			· · · · · · · · · · · · · · · · · · ·
[]	Others. Specify		
	· · · · · · · · · · · · · · · · · · ·		······································
Monitore			
	Printed name	Signature	Position/Designation
		· · · · · · · · · · · · · · · · · · ·	
Received b	by:		
Signature:			
Printed Na	ame:		
Position/D	esignation:	<u> </u>	
Date:			

•					_				
								A.O. NO. 2020-	0014
			COVID-19.T	ESTINGEARORA	TORY				ANNEX B
			LABORATO	RY ASSESSMENT	TOOL				
I PARTICIPANT'S	INFORMATION				l	18. DETAILS OF ASSESSMENT			
HANE OF PARTICIP	ANT_First Name, MI, Sumane			-		START DATE (dd-mmm-yyy)			
SECTION						(dd-mmmvyyy) KANE/R OC PROCEENINE/R IDNIs and Wile			
POSITION									
II. EVALUATOR'S	INFORMATION					IV. SCORING GUIDE PER KEY AREA		þ	1
HAND OF CEALONI						1	Requirement met/Present/With		Requirement not
SECTION							complete svidence		
DESIGNATION							partially met/incomplete	N/A	Not molecula
						0.5	enidence of compliance (Use		
P050100		•			·		SCORE	PENA	RKS
1 1	ACILITIES AND WORKFLOW		inem .			· · · · · ·	George		
1.1.1	Design and location of the facility appropriate Refigient source is periodicity appropriate	a to the leboratory reads	handlan BCR testing)	· · ·					
1,1,3	Spece is used officiently with appropriate ap	Upment							
1.1.5 1.1.5	aboratory environment ensures earlery to the aboratory bas back to electrical power stat	e work and the workor			_				
121	Projection of the second	les for specimen mosphon and hands	ng	· · · · · · · · · · · · · · · · · · ·					•
1.2.2	Dedicated space, equipment and consumation Dedicated space, equipment and consumation	les for nucleic acid autraction les for reagent storage and handling a	icixiles						
124 125	Dedicated space, equipment and conjumeb Work is semiad out in a unidirectional workfi	les for clencal activities (cleta <u>encoder</u> ow (from clean to dirty)	a, result generation, reporting)						
131	Nechanism for access restriction to mathoriz	ad personnel is in place	<u> </u>		•• •			· 	
132	Veniences required signages are posted on it	ne laborationy doors (i.e. nature of work	ubeing performed in the more, bloba	zard sign (f applicable)		Rev Score			
						Average Score			
	PERSONNELREQUIREMENTS					· · · · · · · · · · · · · · · · · · ·		· · · · .	· · · ·
21.1	Lines of supervision and accountability relev aboratory top management ensures that te	ent to Molecular Detection of Respirat scratory facilities are adequate to conc	sury veryses are clear to all statt such Molecular Delection of Respirat	UTY 1411503					
213 214	Evidence available to show taboratory super Evidence available to show taboratory super	with start are held to discuss operate start enterally reviews test workshoets	and results for accuracy and compl	elaness, and indicate need fo	r follow-up act	6018			_
2.1.5	aboratory supervisor ansures that sufficien	t supplies, respects and functional ex-	upment an available to handle the la el and executed	abonatory/s workload					
21.6	Accreacy supervisor ensures the two calls Anangoments are made for qualified back-u	in the residue, related have been until the staff to sustain services during sche	eduled staff ebsences (eq. Vacalion.	study, matematy or paternity)oave)				
221	Staff with appropriate educational backgroup	of for the position	filed accordingly			<u> </u>			
223	Technical laboratory staff with valid license (f applicable)							
23.1	Laboratory supervisor and staff with orientat Laboratory supervisor and staff with training	ion on Molecular Detection of Rospira on Blossfely	liony vincens						
23.3	Laboratory staff with training on the Molecul Manual of Procedures and Laboratory Work	er Detection of Respiratory viruses Instructions are on Re and eccession	to all statt						
24.1	Laboratory with proof of proficiency for PCR	detection of respiratory viruses			_	<u> </u>	[l	
2.5.1	aboratory has identified a processing ache	dule (for specimen collection/handing	PCR testing, result reporting)		• • •				
25.2	Worldoed is commensurate to the number o	<u></u>				Raw Score			
3	ASSAY REQUIREMENTS								
3,1,1	System for inventory management is available depute time in adjaced for registerichment	is (includes warning system for expiry	y and stock replenishment)	-	_				
31.3	Procurement planning system in place acco Reactents and succises on stock are ecoror	unte for estimated delays, respent to: nate according to laboratory protocol r	pry, etc. to ensure continuous supply aquirements	yof metadols and reagents					
31.5	Respons labelled appropriately with the idea Responts and supplies stored under appropri-	nity, concentration, date of prepension rials conditions (eg. Temporature, hu	n, date of opening and scoliny, storag midny, light, containment)	e conditions and name of per	nion who prepi	ered			
3.1.7	Storage area of responts asperate from that	of specimens to avoid contamination							.*
321 322	Controls are eliquoted to working volumes. Controls are stored under proper storage op	nditions (separate from clinical specifi	menta, -20 [°] C)						
123	Non-conformances relevant to controls and An antiferences of the	decumented and acted upon	_						
33.1	Occurrentation system for acceptance and Specimens are stored in dedicated compart	rejection of specimens is present ments (e.g. unafiquoted specimens, a	Aquated epochters for leating)						-
333	A system for specimen becking and ershift Access to specimen starage area is restrict	ed to authorized personnel			·				
335.	Solition of the second s	and in the maximum of the specim		· · · · ·				· · · ·	<u> </u>
34.1	Biosafety cabinet for specimen inactivation/	iquing/nachaton/nucleic acid etc	racion						
343	Microcentrituge (2mL rotor capacity) Variable volume bioathus	· · · · · · · · · · · · · · · · · · ·							
34.5 34.0	Real-sime PCR mechine An equipment inventory system/menutorme	nt is maintained							
347	All critical equipment are certified/calibrated Temperature of storage compartments (free	periodically as appropriate, and recor- per, refrigenetor) is being monitored	da are available						
3.4.9	All equipment appropriately located to ensure Equipment are cleaned and maintained wall	a safety					<u> </u>		
351	In this constitues Secure and safe place available for archive	d raw deta, documents and reports					<u> </u>		
3.5.2	Access to laboratory data is restricted to au	norusial personnel anty				Haw Scott			ļ
	QUALITY CONTROL					Average 3000	··		<u></u> _
4.1.1	Responds are pre-leaded prior to routine une						I		
422	Controls are pre-jected prior to routine use	100							
4.71	Verfaceton system for detection of every la	leboratory data encodino is in ninca							
432	Verification system for monitoring PCR run Mechanism for excluding investor case are in-	velicity is in place resigned and repeated (according to	analysis of probable cause of error)	ls in place					
43.4	Vandication system for review of results pric	r jo mianne is in place					1		
						Average Bcor		<u> </u>	
HRAL RATING	Confident and Workshim				ų –				
2	Personnel Requirements		0]				
	Quality Cantral]				

.

,

A.O. NO. 2020- 0014 ANNEX B2	A.O. NO, 2020-	0014 ANNEX 62
---------------------------------	----------------	------------------

COVID-19 TESTING LABORATORY LABORATORY BIOSAFETY ASSESSMENT TOOL

-

-

.

1 0401000	INT'S INFORMATION		III. DETAILS OF	ASSESSMENT		
INCOLOUM DE LA			START DATE			
NAUE OF PARTICIPANT First Name, MI, Summer			END DATE	- 		
55CTION			(dd-mmm-yyyy)	l		
DEBIGNATION NAME/B OF PROCEDURE/S (PM/s and W/s						
POSITION						
II. EVALUAT	OR'S INFORMATION		IV. SCORING G	UIDE PER KEY AREA	0	Requirement not
NAME OF EV	ULATOR First Kame, 12, Surrame			met/Present/With complete	-	mel/Absent
				on dates		1
					LIVA .	Net and able
DESIGNATIO			0.5	Requirement partially	NA	Гюх аррисасна
				compliance (Use Remarks		1
noemou				column to ente down comments)		
POSITION						
THE PARTY AND	AN LEAD REAL AND A CONTRACT OF THE ACCOUNT OF THE A	SCORE		REMARKS		
1. Prior to c	enducting laboratory task					
1.1.	Laboratory personnel received appropriate immunization (e.g. (Millenza)					
1.2	Laboratory personnel are proticient and trained to work with infectious egents.					
2. The fallo	ving practices are prohibiled in the faboratory:					
2.1.	Esting, drinking, smoking, handling contact lanses, applying cosmetics, or storing food in leb areas					
2.2.	Use of open-toed shoes					
2,3,	Saning in vizo cuazes or moun process					
2.5	Use of carpets, rugs, or fabric covered chains in leboratory	_				
2.8.	Presence of children/minors within working areas					
3. Standard	presides Desence matters may be twenting being a being and effer working with mission's basedous materials.					
32.	Use and unnecessary manipulation of sharps and glasswares are minimized					
3.3.	Use of punchase resistent containers for sherps disposel					
- ^{3.4.}			1			
3.5.	Potentially infectious motorials are decontaminated before disposal, using appropriate chemical disinfectant and/ or suboctave.		<u> </u>			
3.6.	teporatory waste proceeds norm ereas of tomor constitutions (i.e., crean) to preas of inginer constitutioned [i.e., carry block		<u> </u>			
17.	Gloves are changed when contaminated, integrity has been compromised, or when otherwise necessary.					
38.	Disposable gloves and other PPE are not weshed or roused			_		
4, Special F	raçtizos					
41	Potentially infectious materials are placed in a durable, leak proof container during collection, hankling, processing, storage, or transport within a facility.					
<u></u> _	All procedures implying the manipulation of infectious materials that may generate an aerosol are conducted within a BSC or		1			
	other physical containment devices. These may include pipetting, centritiging, grinding, blending, shaking, mixing, sonicaling,					
42	topening containers of intectious materials, and herresping intected tosues Cotecting samples, adding materials, or transferring culture buds from one closed system to another are performed in a		<u> </u>			
4.0.	manner that prevents the release of aerosols or the contamination of exposed surfaces.					
44	Contribugation of infectious material where inhalishon is the primary route of strection are carried out in search copy (or rotors) that are unicacied in a BSC.					
	Protective clothing appropriately disposed or laundered within the institution. Laboratory clothing are not taken home by		1			
45.	employees for cleaning.		1			
4.9. 5 Use of P	To be and her work outside the race work of a control of access the same matances one region into addice grower				[
6.1.	Appropriate and dedicated PPE exclusively worn and stored specifically in sech containment zone		<u> </u>			
52	Dedicated footwear are used and available			<u> </u>		
5.3.	Gioves are worn when handling infectious material.					
5.4.	Protective laboratory coats, gowns, smocks, aprons of scrub suits designated for laboratory used inside the laboratory Few and take protection (copples, mask, face shield or other splatter guard) are used for anticipated splashes or sprays of		<u> </u>			
5.5.	infectious or other hezardous materials when the microorganisms must be handled outside the BSC or containment device.		<u>+</u>			
6.6.	Availability of Respirator (N95, N100, P100 and PAPR)		- <u> </u>			
57.	(All at rest personnel exposed to any potential and/sec at the locorder y person respirator ris rest					
5.9.	PPEs available are dutable and of good quality.					
6. Use of L	iberatory Safety Equipment (Primary Barrier)		· ·			
6.1.	Contided BSCs are provided and used based on risk assessment.				1	
62	and should be free from obstruction.			_		
7. Laborate	ry Access		-1			-
7.1.	Access to containment zone is limited to authorized personnel.					
8. Laborali	In a section was a sink for band washing.]	
8.2	Emergency eventsh and shower equipment provided inside the laboratory based on risk assassment.		1		1	
8.3	Ample space provided for the safe conduct of leboratory work and for cleaning and maintenance.				4	
8.4.	Dedicated facility for non laboratory activities (e.g. meeting, meet break)				1	
8.5	Autoclave or other means of decontemination available pretendory in dose proximity to the laboratory.	<u></u>	- <u> </u>	· · · · · · · · · · · · · · · · · · ·	1	
9 Adminiz	trative Control and Oversight					
9.1.	Laboratory-Specific Biosafety Manuel available and accessible for all				ł	
9.2	Laboratory has documented local (biological) risk assessment				1	
9.3	Procedures / guidelines for safe and secure transport of weste from laboratory to designated storage / decontamination area				1	
9.4	Restriction of work with infectious material and high risk jaboratory procedures				-	
6.4	A istoratory signage is posted and incorporates other information including the (aboratory's biosafety level, the supervisor's forme (or other responsible personnel) telephone number, and specific entryiatil resultaments (vectivation, PPE).					
9.6.	Personnel health services program (medical survaillance, immunication)				4	
9.7,	There is a established Emergency Response System for:	Į	<u> </u>	_	-	
9.7.1	Accidents	<u> </u>		.	1	
9.7.2.	Medical Emergencies		1		1	
974	Naturel Disastera	<u> </u>				
0.7.5	Facility/Containment Device	1				
10. Record	s and Documentation					
10.1,	Records of the following are kept on his: Building and equipment maintanance, report, inspection, testion, calibrations or certification, including performance vanification				1	
10.1.	and testing records	 	1		-	
10.1.1	Valdation and routine verification of decontamination technologies and processes				4	
10.1.	Training, proficiency, license, permits of laboratory staff		+		-	
10.1.	. Incident reports, accidents, incidents and related investigations conducted	· · · · ·	+		1	
10.1.	TAbendar unternited surgitation of standing of the standard and standard in the standard and standard				_	

•

.

Annex 2 Risk assessment template

Although a qualitative approach to combining likelihood and severity parameters in a risk matrix is provided as a risk evaluation method here, it is important to note that quantitative (for example, simple numerical scoring schemes to complex mathematical models) and hybrid (semi-quantitative) methods can also be used for risk evaluation. Laboratories should use a risk evaluation/assessment method that best meets their unique needs, without excluding the possibility of developing customized evaluation approaches, scoring methods and definitions of the parameters.

While this template was primarily developed for biosafety risk assessment, it can also be used for general safety risk assessment of laboratory activities, especially when the biosafety and general safety risks are interlinked, for example, sample collection and transport, where appropriate and applicable.

Institution/Facility name	
Laboratory name	
Laboratory manager/Supervisor	
Project titles/Relevant standard operating procedures (SOPs)	
Date	

If using this template, complete all sections following the instructions in the grey boxes. The instructions and bullet points in the grey boxes can be copied into the text boxes beneath the instructions and used as prompts to gather and record the necessary site-specific information. The grey instruction boxes can then be deleted, and the text remaining will form a risk assessment draft. This draft must be carefully reviewed, edited as necessary and approved by the risk assessment team members.



STEP 1. Gather information (hazard identification)

Instructions: Provide a brief overview of the laboratory work and summarize the laboratory activities to be conducted that are included in the scope of this risk assessment.

Describe the biological agents and other potential hazards (for example, transmission, infectious dose, treatment/preventive measures, pathogenicity).	
Describe the laboratory procedures to be used (for example, culturing, centrifugation, work with sharps, waste handling, frequency of performing the laboratory activity).	
Describe the types of equipment to be used (personal protective equipment (PPE), centrifuges, autoclaves, biological safety cabinets (BSCs)).	
Describe the type and condition of the facility where work is conducted.	
Describe relevant human factors (for example, competency, training, experience and attitude of personnel).	

Laboratory biosafety guidance for novel coronavirus (2019-nCoV): Interim Recommendations

Describe any other factors that may affect	
laboratory operations (for example, legal, cultural,	
socioeconomic).	



STEP 2. Evaluate the risks

Instructions: Describe how exposure and/or release could occur.				
What potential situations are there in which exposure or release could occur?				
What is the likelihood of an exposure/release occurring?				
x Unlikely: not very possible to occur in the near future				
x Possible: feasible to occur in the near future				
x Likely: very possible to occur in the near future				
What is the severity of the consequences of an exposure/release (negligible, moderate, severe)?				

Instructions: Evaluate the risk and prioritize the implementation of risk control measures. Circle the initial (inherent) risk of the laboratory activities before additional risk control measures have been put in place.

- Note:
 - x When assigning priority, other factors may need to be considered, for example, urgency, feasibility/sustainability of risk control measures, delivery and installation time and training availability.
 - x To estimate the overall risk, take into consideration the risk ratings for the individual laboratory activities/procedures, separately or collectively as appropriate for the laboratory.

		Likelihood of exposure/release			
		Unlikely	Possible	Likely	
Consequenc	Severe	Medium	High		
e of	Moderate	LOW	Medium	High	
exposure/rel ease	Negligible 7969 losa		1.09V	Medium	
Laboratory activity/procedure		initial risk (very low, low, medium, high, very high)	Is the initial risk above the tolerance level? (yes/no)	Priority {high/medium/lo w)	
			1		

Laboratory biosafety guidance for novel coronavirus (2019-nCoV): Interim Recommendations

Select the overall initial risk.	$\sum_{i=1}^{N} P_i H_i$	□ Medium	□ High	tu Senyenigh
Should work proceed without additional risk control measures?		Yes 🗆	INo	



STEP 3. Develop a risk control strategy

Instructions: List any requirements that have been prescribed by international and national regulations, legislation, guidelines, policies and strategies on biosafety and biosecurity.

Describe the measures required by national	
legislation or regulations (if any).	
Describe the measures advised by guidelines, policies and strategies (if any).	

Instructions: Describe the resources available for risk control and consider their applicability, availability and sustainability in the local context including management support.				
Are resources sufficient to secure and maintain potential risk control measures?				
What factors exist that may limit or restrict any of the risk control measures?				
Will work be able to proceed without any of the risk control measures; are there alternatives?				



STEP 4. Select and implement risk control measures

Instructions: Describe where and when risk control measures are needed, the level of **residual** (remaining) risk when these risk control measures are in place, and an assessment of the availability, effectiveness and sustainability of the risk control measures.

Laboratory activity/procedure	Selected risk control measure(s)	Residual risk (very low, low, medium, high, very high)	Is the residual risk above the tolerance level? (yes/no)	Are risk control measures available, effective and sustainable? (yes/no)
	·			

Instructions: Evaluate the **residual** risk that remains after risk control measures have been selected to determine if that level of risk is now below the tolerance level and whether work should proceed. Circle the **residual** risk of the laboratory activities after risk control measures are in place.

		Likelihood of exposure/release)
		Unlikely	Possible		Likely
	Severe	Medium	High		ter ligh
Consequence of	Moderate		Medium		High
exposure/release	Negligible	the set of the			Medium
Overall residual risk:					
-		an e leve and	owy Medium	High	$[\lambda_{22},\lambda_{22}] \in \mathcal{K}(k)$

If the residual risk is still above the risk tolerance level, further action is necessary such as additional risk control measures, based on the initial risk evaluated in STEP 2, redefining the scope of work such that it falls below the risk tolerance level with existing risk control measures in place or identifying an alternative laboratory with appropriate risk control strategies already in place that is capable of conducting the work as planned.

Should work proceed with selected risk control measures?	□Yes □No
Approved by (Name and title)	
Approved by (Signature)	
Date	

Instructions: Describe how to communicate risks and risk mitigation strategies to personnel. Provide a mechanism of communication within the laboratory. Describe the process and timeline for ensuring that all identified risk control measures are purchased, have associated SOPs and training has been completed before starting the laboratory work.

Communication of the hazards, risks and risk control measures	
Purchase (and budgeting) of risk control measures	
Operational and maintenance procedures	
Training of personnel	



STEP 5. Review risks and risk control measures

Instructions: Establish a periodic review cycle to identify: changes in laboratory activities, biological agents, personnel, equipment or facilities; changes in knowledge of biological agents or processes; and lessons learnt from audits/inspections, personnel feedback, incidents and/or near misses.

Frequency of the review

Person to conduct the review

Describe updates/changes

Leboratory biosafety guidance for novel coronavirus (2019-nCoV): Interim Recommendations

Personnel/procedures to implement the changes	
Reviewed by (Name and title)	
Reviewed by (Signature)	
Date	

5. Acknowledgements

The following people contributed to the current revision of this guidance:

Stuart Blacksell, Mahidol Oxford Tropical Medicine Research Unit, Thailand; Kathrin Summermatter, Institute for Infectious Diseases, University of Bern, Switzerland.

WHO Health Emergency Programme: Kazunobu Kojima, Rica Zinsky, Zsofia Igloi.

©World Health Organization 2020. All rights reserved. This is a draft. The content of this document is not final, and the text may be subject to revisions before publication. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization.

WHO reference number: WHO/WPE/GIH/2020.1

ANNEX D1 A.O. NO. 2020-0014

12 000 3 3 000 3 000 3 000 3 000 ន្ល 5XIT SERVICE CORRIDOR -25 ▶ (UTILITIES, WASTE, ETC) æ 5639 Ŧ Ì <u>(2</u>) 5 <u>ş</u>ş (Ö) ANTE 23 PCR ROOM 2 1 0 2 2Z коом 6 Ê, ίĝ, (19) (<u>3</u>-23 SPECIMEN HANDLING/ SAMPLE PREP ROOM Ģ ୍ରତି 0 Ø ន្ល **(**()) SPECIMEN 17 -15-22 RECEIVING TEPMPLATE ÷D 2 000 ADDING ROOM <u>(</u>9); ÷ 0 10 \mathcal{O} Ģ T **(**වි) éè Ο 131 SECIM 0 REAGENT 包 3 (i) (i) CHANGE ROCM CLEAN WRITE SHOP 5 ទ្រ ROOM 23 ίĵ ROOM AND SUPPLY ROOM Q ારોહિ 60294 (3) źĈ

REFERENCE PLAN FREE-STANDING COVID-19 TESTING LABORATORY USING RT-PCR

1

LEGEND

- () AUTOCLAVE
- DIOLOGICAL SAFETY CABINET (BSC)
- 3 LAMINAR AIRFLOW (LAF) HOOD
- (REAL TIME POLYMERASE CHAIN
- REACTION (RT-PCR) MACHINE
- (5) VORTEX MIXER
- (G) MICRO CENTRIFUGE
- PIPPETTORS
 PIPPETTE FILTERED TIPS
 PREEZER
 REFRIGERATOR

- Û
- PERSONAL PROTRECTIVE EQUIPMENT (PPE)
- 12 PERSONAL PROTECTIVE EQUIPMENT (PPE)
- CABINET 3 FIRST AID AIT

- 14 COLD RACK
- (S LABORATORY DEEP SINK WITH EYE WASH (S COMPUTER () PASS BOX

- (& WASTE BIN
- LABORATORY STOOL (9
- εŌ
 - COMPUTER CHAIR

102

- 2) 22 HAND WASHING SINK WITH EYE WASH LABORATORY COUNTER
- MINIFUGE
- 23
 - CONVENTIONAL PCR MACHINE
 - STAINLESS STEEL UTILITY SINK
- źĞ SPILL KIT PCR HOOD
- 27:

NOTE:

RECEIVING

THE PROPOSED COVID- 19 TESTING LABORATORY SHOULD BE LOCATED IN A SEPARATE LOCATION OUTSIDE AN EXISTING INSTITUTION WHERE THERE IS LESS FOOT TRAFFIC FOR THE PROTECTION OF STAFF AND PUBLIC.

GRAPHICAL SCALE: 0.50 1

5750

ß

à

ĝ

<u></u>	TITLE	NOTED BY:	SHEET NO.
DEPARTMENT OF HEALTH CENTRAL OFFICE	REFERENCE PLAN' SAMPLE PLAN COVID TESTING LABORATORY	MARIA ROSARIO SINGI-VERGEIRE, MD, MPH, CESO	1 OF 2 version 3.0 PRPD BY: WHFSRB & RITM
-		- /44	

GENERAL NOTES

ວວດ່ອ

I. DOOR WIDTH MUST BE AT LEAST I.OO METER IN ORDER TO ACCOMMODATE ENTRY AND EXIT OF EQUIPMENT. ALSO, PROVIDE VISION PANEL/S ON ALL DOORS AS APPLICABLE. THE DOORS MUST BE LOCKABLE AND SHALL HAVE A SELF CLOSING MECHANISM. ADOPT CHEMICAL RESISTANT AND EASY TO CLEAN DOOR FINISH.

WINDOWS

1. THE EXTERNAL/ INTERNAL WINDOWS SHALL EMPLOY FIXED TEMPERED/SAFETY GLASS WINDOW.

WALLS

- 1. ALL WALLS AND PARTITIONS SHALL BE STRUCTURALLY SOUND, SAFE AND MADE OF STURDY, IMPERVIOUS (WATER PROOF, IMPENETRABLE, IMPERMEABLE) MATERIALS AND EASY TO CLEAN, WITH ANTI-BACTERIAL/ANTI-FUNGICIDAL CHEMICAL RESISTANT FINISHES.
- 2. INTERIOR WALLS/ PARTITIONS MUST BE FLOOR TO FLOOR HEIGHT TO PREVENT CROSS CONTAMINATION AND FOR FIRE SAFETY COMPARTMENTALIZATION.

CEILING

- 1. THE CEILING HEIGHT SHALL BE AT LEAST 2.60M IN ORDER TO ACCOMMODATE BIOLOGICAL SAFETY CABINET.
- 2. THE CEILING SHALL BE STRUCTURALLY SOUND, SAFE AND MADE OF STURDY IMPERVIOUS (WATER PROOF, IMPENETRABLE, IMPERMEABLE) MATERIALS AND EASY TO CLEAN. ANTI-BACTERIAL/ANTI-FUNGICIDAL CHEMICAL RESISTANT FINISHES.

FLOOR

1. THE FLOOR MATERIAL AND FINISH MUST BE MONOLITHIC, STRUCTURALLY SOUND, SAFE AND MADE OF STURDY IMPERVIOUS (WATER PROOF, IMPENETRABLE, IMPERMEABLE) MATERIALS AND EASY TO CLEAN. ANTI-BACTERIAL/ANTI-FUNGICIDAL CHEMICAL RESISTANT FINISHES WITH COVED CORNERS.

EXHAUST

- 1. FOR THE SPECIMEN RECEIVING AND SPECIMEN HANDLING/ SAMPLE PREP ROOM, THE EXHAUST MUST PRODUCE AT LEAST 12 AIR CHANGES PER HOUR (ACH) AND MUST BE DIRECTED AWAY FROM PEOPLE AND ADJACENT STRUCTURES.
- 2. FOR THE PCR ROOM, THE EXHAUST MUST PRODUCE AT LEAST & AIR CHANGES PER HOUR (ACH) AND MUST BE DIRECTED AWAY FROM PEOPLE AND ADJACENT STRUCTURES.
- 3. THE REAGENT PREPARATION ROOM SHALL HAVE A POSITIVE PRESSURE ROOM CONDITIONED. ALSO, IT SHALL HAVE FILTERED AIR SUPPLY WITH A 90-95% EFFICIENCY.
- ADDITIONAL EXHAUST REQUIREMENT TO BE CONSIDERED IF THE AREA HAS ADJACENT BUILDINGS, STACK SHOULD NOT HAVE GOOSENECK OR CAP AND SHOULD BE AT LEAST 3.00M HIGHER THAN THE HIGHEST POINT OF THE ROOF OR ADJACENT BUILDING.
- 5. INSTALLATION OF MAGNEHELIC GAUGE IS RECOMMENDED FOR MONITORING NEGATIVE PRESSURE FOR SPECIMEN RECEIVING AREA AND SPECIMEN HANDLING ROOM.

AIR CONDITIONING

1. ALL AIR CONDITIONING UNIT MUST BE SPLIT TYPE, AIR DIRECTION SHOULD BE AWAY FROM THE SAFETY CABINETS (BSC, PCR HOOD AND LAMINAR AIR FLOW)

PASS BOX

- 1. FOR INTERNAL PASS BOX, IT MUST HAVE A MINIMUM APPROXIMATE INTERNAL DIMENSION OF 0.30M X 0.30M X 0.30M (LXWXD), ELECTRICALLY AND MECHANICALLY INTERLOCKED.
- 2. FOR SPECIMEN RECEIVING PASS BOX, IT MUST HAVE A MINIMUM APPROXIMATE INTERNAL DIMENSION OF 0.40M X 0.40M (LXWXD), ELECTRICALLY AND MECHANICALLY INTERLOCKED.

CODES

1. ALL PLANS AND DRAWING REQUIREMENTS SUCH ARCHITECTURAL, CIVIL, ELECTRICAL, LIGHTING AND POWER, SANITARY AND PLUMBING AND MECHANICAL, AND OTHER RELATED TRADES SHALL BE IN ACCORDANCE WITH ALL RELEVANT AND EXISTING CODES OF THE PHILIPPINES AS APPLICABLE.

OTHERS

- I. INSTALLATION OF INTERCOM FOR ALL ROOMS IS RECOMMENDED.
- 2. PROVISION FOR TOILET AND OTHER AMENITIES FOR THE LABORATORY STAFF SHALL BE LOCATED OUTSIDE BUT EASILY ACCESSIBLE TO PREVENT CONTAMINATION.

	GRAPHICAL SCALE: 0 0.50 1 2 3	5
	Ban Alfr of Ban Performan	πιε
i	DEPARTMENT OF HEALTH CENTRAL OFFICE	REFERENCE PLANV SAMPLE PLAN COVID TESTING LABORATORY

W	
	PRPD BY:
MARIA ROSARIO SINGH-VERGEIRE, MD, MPH, CESO IV	HFSRB & RITM

SHEET NO.

NOTED BY:

A CONTENT OF THE SECOND POINT OF THE SECOND PO

Republic of the Philippines Department of Health HEALTH FACILITIES AND SERVICES REGULATORY BUREAU

Annex D2

A.O. No. 2020-<u>0014</u>

CHECKLIST FOR REVIEW OF FLOOR PLANS COVID-19 TESTING LABORATORY USING RT-PCR

1001055.		Deuteur 4st	ond	ord
)ate:		Review: 1*	Z	3
DUVOIC				
. PHISICA	AL PLAN I Clinical Work Area			
	1 1 2 Deceiving (Sounter		
		1.2.1 Dass Boy going to Sna	cimen Receivir	na Room
	1 1 3 Specimen B	Pereiving Doom	CITIEII IVECEIAII	ig Noom
	1.1.5 Speciment N	1 3 1 Antercom with Handwa	shina Sink	
	i.i i.i	1.3.1 Anterootti with Lab	oratory Deen Si	nk
	1 1	1.2.2 Page Roy going to Sne	oimon Handlin	ni Samola
		Propagation Boom/ P	CIMEN Handling	gi Sample
	1.1.4 Change Boy	ereparation Room/ Pl	PPE Dook and I	Jompor
	1.1.4 Change Roo	In with hand washing slik,	n Boom/ Bro BC	
<u> </u>	1.1.5 Specimen F	Tanuiny/ Sample Freparatio	aratany Doon Si	
		1.5.1 Work Counter with Lab	oratory Deep Si	
	1.1	1.5.2 Pass Box going to Rea	gent Preparation	
	1.1	1.5.3 Fass Box going to FCF	r with Llondwor	shing Sink
	1.1 C Decemb Dr.	anarotian Boom	in with hanuwa	Shiriy Sink
	1.1.6 Reagent Pre	eparation Room	aratan (Daan Si	nl:
		ddiag Doom	oratory Deep St	IIK
·		aaing Room 1.7.1 Merk Counter with Leb	aratan Daan Si	nk
	1.1.9. Delumerece	Chain Beastian (BCB) Bea	oratory Deep Si	нк
	1.1.6 Polymerase	Chain Reaction (PCR) Roo	(I) aratan (Daan Si	ml.
		Chan and Supply Boom	oratory Deep Si	пк
		1 9 1 Mark Counter		
		1.9.1 WORK Counter		
1	2 Support Area	ridan		
		TIGOF		
. PLANNI	NG AND DESIGN		-	
2	1 Floor plans properly i	identified and completely lab	eled	
2	2 Doors, windows, fixtu	res, furniture and equipmen	t are properly la	id out.
2	3 Meets prescribed fun	ictional programs:		
	2.3.1 Zonina Rea	uirement:		
	2.2	2.1.1 Laboratory location sha	all have less foo	t traffic yet
		accessible for receiving	of specimen.	•
	2.2	2.1.2 The flow of traffic of sp	ecimen aoina to	specimen receivir
	· · · ·	counter shall not pass t	hrough general	public areas.
	2.3.2 Floor plan s	suggests unidirectional work	low process fro	n receiving of
	specimen to	results data processing as	applicable.	5
	2.3.3 Specimen F	Receiving Room. Specimen	Handling/ Samp	le Preparation
	Room/ Pre-I	PCR Room and PCR Room	have direct acc	ess to service
	corridor.			
	~~~~~~~			
	2 3 4 Service Cor	rridor has a minimum clear a	ind unobstructed	width of 1.20

2.3.5 Door access from service corridor have at least 1.00 meter clear width to
accommodate entry and exit of equipment as applicable.
2.3.6 Internal windows are laid out to promote visual observation between
work rooms as applicable.
2.3.5 Provision for toilet and other amenities for laboratory staff are located
outside but easily accessible to prevent contamination.
2.4 Conforms to the applicable codes as part of professional service
2.4.1. Exits restricted to the following types: door leading directly outside the
building, interior stair, ramp, and exterior stair.
2.4.2 Minimum of two (2) exits, remote from each other.
2.4.3 Exits terminate directly at an open space to the outside of the building.

.

### COMMENTS:



### Republic of the Philippines Department of Health HEALTH FACILITIES AND SERVICES REGULATORY BUREAU

Name of Health Facility:	 -	
Address:		
Date:		

### COMMENTS:

# HEALTH FACILITIES EVALUATION AND REVIEW COMMITTEE (HFERC) [ ] Approved [ ] Disapproved

Chairperson, HFERC

Vice-Chairperson, HFERC

Member

Member

Member

Member

Member

Member



Republic of the Philippines Department of Health HEALTH FACILITIES AND SERVICES REGULATORY BUREAU

### APPLICATION FOR LICENSE TO OPERATE COVID-19 TESTING LABORATORY

Name of Laboratory	:	
Address of Laboratory	:	
	No. & Street	Barangay
	City/ Municipality	Province Region
Telephone/ Fax No.	· · · · · · · · · · · · · · · · · · ·	
Head of the Laboratory	•	·
Name of Owner	·	
Contact Number	·	
License No. (if applicable)	•	
Date Issued	:	
Expiry Date	۰	
	[] Initial	[] Renewal
Classification According to	)	
Ownership	: [ ] Government	[] Private
Institutional Character	: [ ] Hospital-based	[] Non-hospital-based
Service Capability	: [] Add-on service to Genera : [] Limited Service Capabili	l Clinical Laboratory ty to COVID-19 Testing

## **Checklist of Application Documents**

Α	B
Documents	Please put ( 🗸 )
1. DOH Approved PTC and floor plan	
2. Notarized list of personnel, including photocopies of valid PRC identification	
card. (ANNEX A)	
3. List of equipment with specifications, reagents, and supplies (ANNEX B)	
4. Copy of Certificate of Product Registration (CPR) from Food and Drug	
Administration of all equipment and reagents.	
5. Technical Procedure Manual or Manual of Operations for COVID-19 testing	
6. For renewal, a copy of NEQAS, Certificate of Performance with PASSING	
results, conducted by RITM.	

Name and Signature of Applicant

**Date of Application** 

Form-COVID19-A Revision:00 04/07/2020 Page 1 of 4

## Acknowledgement

•

REPUBLIC OF THE PHILIPPINE CITY/ MUNICIPALITY OF	ES ) ) S.S.			
I,	,, of	legal age, _	, a	resident of
Name	Civil Status		Age	
	, after havi	ing been swor	n in accordanc	e with law
Address				
hereby depose and say that I a	am executing this affidavit to at	ttest to the co	mpleteness an	d truth of the
foregoing information and the a	attached documents required for	r the establis	hment/operati	ion of health
facility pursuant to existing rule	es and regulations. That the un	ndersigned is a	aware and info	med that any
misrepresentation, falsification/d	leception herein can cause the	denial of my a	pplication.	
			Cianoturo	
			Signature	
Refere me this da	w of	20	in the City/Mu	nicipality of
		2	iont with Comm	
, P	mippines, personally appeared	The above and		unity
	issued on		at	· · · ·
Known to me to be the same pers	son/s who executed the foregoin	ing instrument	and they ackr	iowledge to me
that the same is their free act and	deed.			
Owner	Community Tax Numbe	ar	lesued at/ or	•
Owner	Community Tax Number	<u>,</u>		
known to me to be the same person		instrument and	they acknowle	dae to me that
KHOWH to the to be the same person	is who executed the foregoing a	and the fit and	They downowic	
the same is their free act and deed.				
IN WITNESS WHEREOF,	I have hereunto set my hands th	nisday o	f	, 20
Doc No Page No		NOTA My Comr	NRY PUBLIC	ì
Book No.		Dec.	31, 20	
Series of				

-

Annex A

•

List of Personnel

Name of Laboratory Address of Laboratory

-

.

•••••

Cimoturio	DIBIIALULE									Annex A- List of Personnel Form-COVID19-A Revision30 040772020 Page 3 of 4
Date of Birth	(mm/dd/yr)									
id	To									
Val	From	_								
PRC Reg.	No.						-			
Company I.D.	No.				-					
Designation/	Position									
	lame									

-

•

.

Annex B

List of Equipment, Supplies, and Reagents

Name of Laboratory Address of Laboratory

ype of Equipment Supplies, and Reagents	Manufacturer	Serial No. / Lot No.	<b>Expiration Date</b>
			Annex A- List of Personnel Forn-COVID19-A Revision30 040772020 Page 4 of 4

-